Holen Sie sich die Stockscreener-App
1.18
3.28%
-0.04
Handel nachbörslich:
1.18
Ocugen Inc Aktie (OCGN) Neueste Nachrichten
Ocugen's gene-agnostic eye therapies could reshape late-stage care - MSN
Ocugen, Inc.'s (NASDAQ:OCGN) Profit Outlook - Moomoo
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen (NASDAQ: OCGN) shareholders back pay, elect directors and confirm new CMO - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
OCGN: All agenda items, including director elections and compensation votes, were approved - TradingView
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Ocugen Inc stock (US67577C1053): pipeline updates keep biotech investors watching - AD HOC NEWS
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Inc stock (US67577C1053): Short interest jumps as investors weigh biotech pipeline - AD HOC NEWS
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
OCGN Stock Rallies On Wall Street Optimism For Clinical Pipeline: Retail Awaits New Data - Stocktwits
· Analyst Forecast - MLQ.ai
How The Ocugen (OCGN) Investment Story Is Evolving Without New Analyst Guidance - Yahoo Finance
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Why Did OCGN Stock Rise Today? - Stocktwits
Why is Ocugen (OCGN) down 10.7% since last earnings report? - MSN
Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report? - Yahoo Finance
Ocugen Consolidates Financial Leadership Under New Accounting Officer - The Globe and Mail
Ocugen (NASDAQ: OCGN) CFO assumes principal accounting role - Stock Titan
Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care - Yahoo Finance
Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data? - TradingView
OCGN's Catalyst Calendar for Trial Data and Filings Through 2028 - Yahoo Finance
Ocugen Inc stock (US67577C1053): conference schedule and pre-market moves in focus - AD HOC NEWS
Ocugen to Participate in Upcoming June Investor and Industry Conferences - The Manila Times
Eye gene therapy for blindness hits stage at three June events - Stock Titan
Ocugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exit - MSN
Ocugen (OCGN) Slides 2.13% to $1.38 as Biotech Stock Tests Key Support LevelsMoving Average Ribbon - The Legal Advocate
Ocugen stock dips as Q1 losses widen - MSN
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen Price Target Cut to $11.00/Share From $12.00 by Canaccord Genuity - Moomoo
OCGN Maintained by Canaccord Genuity -- Price Target Lowered to $11 - GuruFocus
Three Speculative Biotech Penny Stocks With Pipeline Catalysts - Kalkine Media
Ocugen Is Maintained at Buy by Canaccord Genuity - Moomoo
Canaccord lowers Ocugen stock price target to $11 on model update By Investing.com - Investing.com South Africa
Canaccord lowers Ocugen stock price target to $11 on model update - Investing.com Australia
CCORF Maintains Ocugen(OCGN.US) With Buy Rating, Cuts Target Price to $11 - Moomoo
FTSE Russell Index Reconstitution Sees Major Changes with Ocugen (OCGN) Joining - GuruFocus
Ocugen (OCGN) Set for Inclusion in Russell 3000 Index Rebalancin - GuruFocus
OCGN Stock Chart | OCUGEN INC (NASDAQ:OCGN) - ChartMill
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):